GLP-1 Peptides Complete Guide 2026 — Every Compound Compared
The GLP-1 peptide category has fundamentally changed the science of weight management. Where previous pharmaceutical approaches produced 5–8% weight loss at best, GLP-1 receptor agonists and their multi-receptor successors produce 15–26% average body weight reduction — results that overlap with bariatric surgery outcomes for the first time in pharmaceutical history.
But the GLP-1 category is expanding rapidly — Semaglutide, Tirzepatide, Retatrutide, Cagrilintide and more are all in this space with different mechanisms, different potency and different evidence profiles. This is the definitive guide to all of them.
🔬 The GLP-1 Revolution: GLP-1 receptor agonists are the first class of weight loss compounds to consistently produce results that medical literature considers "clinically meaningful" — 15%+ body weight reduction. Previous pharmaceutical weight loss drugs topped out at 5-8%. This is why GLP-1 peptides have transformed the weight loss research landscape.
How GLP-1 Peptides Work
GLP-1 (Glucagon-Like Peptide-1) is a hormone produced by L-cells in the small intestine in response to food intake. Natural GLP-1 has a half-life of approximately 2 minutes — it is rapidly degraded by the enzyme DPP-4. Research GLP-1 peptides are modified versions of this hormone with alterations that make them resistant to DPP-4 degradation, dramatically extending their active duration.
GLP-1 receptors are found in multiple locations that are all relevant to weight management:
- Hypothalamus and brainstem: Appetite regulation centres — GLP-1 receptor activation here produces the primary appetite suppression effect
- Stomach: Slows gastric emptying, extending the feeling of fullness after meals
- Pancreas: Stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner
- Heart: Cardioprotective effects — GLP-1 receptor activation has shown cardiovascular risk reduction in multiple trials
- Liver: Reduces hepatic glucose production and fat accumulation
Every GLP-1 Category Peptide Compared
Semaglutide — The Foundation
Semaglutide is the first GLP-1 receptor agonist to demonstrate weight loss results that medical literature considers "clinically meaningful" (>15% body weight). The STEP clinical trial programme is the most comprehensive GLP-1 research ever conducted — over 4,500 subjects followed for 68+ weeks. Average weight loss: 15–18% of body weight at the highest studied dose.
Semaglutide's modification over native GLP-1 includes a fatty acid chain that promotes albumin binding — extending half-life to approximately 7 days, allowing once-weekly injection. It is the most extensively studied compound in this entire category.
PEPTARA price: From $30 per 5mg vial
Tirzepatide — The Current Leader
Tirzepatide adds GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonism to GLP-1 receptor agonism — creating the first "twincretin" compound. The SURMOUNT clinical trial programme demonstrated average 22.5% body weight reduction at the highest dose, with nearly half of subjects losing more than 20% of body weight.
The GIP receptor contribution is multifaceted: GIP receptors on adipose tissue appear to directly regulate fat metabolism; GIP's interaction with GLP-1 signaling appears to produce synergistic appetite suppression; and the combination may explain why Tirzepatide's nausea profile is more favorable than expected for its degree of weight loss.
PEPTARA price: From $28 per 5mg vial
Retatrutide — The Triple Agonist
Retatrutide adds Glucagon receptor agonism to GIP and GLP-1 — creating a "triagonist" with three distinct mechanisms working simultaneously. Phase 2 trial data showed average 17.5% weight loss at 24 weeks — suggesting that with the full trial duration, results exceeding Tirzepatide are likely. The glucagon receptor component adds additional energy expenditure (metabolic rate increase) to the appetite suppression and fat metabolism effects of GIP and GLP-1.
PEPTARA price: From $70 per 5mg vial
Cagrilintide + Semaglutide (CagriSema)
Cagrilintide is not a GLP-1 agonist — it is an amylin analog. Amylin is a hormone co-secreted with insulin that regulates post-meal blood sugar and, at the brain level, works synergistically with GLP-1 to suppress appetite through different neural pathways. The combination of Cagrilintide + Semaglutide (now being studied as "CagriSema") has shown preliminary results of 22–25% weight loss in early trials — comparable to Tirzepatide through a completely different dual mechanism.
PEPTARA price: From $120 per bundle
Mazdutide (GLP-1 + Glucagon)
Mazdutide is a dual GLP-1/Glucagon receptor agonist — adding glucagon receptor agonism to GLP-1 agonism without the GIP component. The glucagon component increases basal metabolic rate (energy expenditure) while the GLP-1 component suppresses appetite. Clinical data shows meaningful weight loss in Chinese populations, making it an important compound for global weight loss research.
PEPTARA price: From $75
Survodutide (GLP-1 + Glucagon)
Survodutide is another GLP-1/Glucagon dual agonist, developed primarily by Boehringer Ingelheim. It shares the mechanism of combining appetite suppression (GLP-1) with metabolic rate increase (Glucagon) and has shown promising weight loss data in phase 2 trials. Also being investigated for non-alcoholic steatohepatitis (NASH) — fatty liver disease.
GLP-1 Peptide Comparison Table 2026
| Compound | Receptors | Avg Weight Loss | Relative Cost | Evidence Level |
|---|---|---|---|---|
| Semaglutide | GLP-1 | 15–18% | $ (from $30) | ★★★★★ Extensive |
| Tirzepatide | GLP-1 + GIP | 20–25% | $ (from $28) | ★★★★★ Strong |
| Retatrutide | GLP-1 + GIP + Glucagon | 24–26% (est.) | $$$ (from $70) | ★★★☆☆ Phase 2 |
| CagriSema | GLP-1 + Amylin | 22–25% (est.) | $$$ (from $120) | ★★★☆☆ Phase 2-3 |
| Mazdutide | GLP-1 + Glucagon | 16–20% (est.) | $$ (from $75) | ★★★☆☆ Phase 2-3 |
| Survodutide | GLP-1 + Glucagon | 15–19% (est.) | $$ (from $75) | ★★★☆☆ Phase 2 |
| AOD9604 | GH fragment (fat cells) | Complements GLP-1 | $ (from $58) | ★★★☆☆ Moderate |
| HGH Frag 176-191 | GH fragment (fat cells) | Complements GLP-1 | $ (from $45) | ★★★☆☆ Moderate |
How to Choose the Right GLP-1 Peptide
- First-time GLP-1 researcher: Start with Semaglutide — most evidence, most predictable, most guidance available
- Maximum weight loss (40+ lbs): Tirzepatide — the best-evidenced option for maximum results
- Previous Semaglutide plateau: Upgrade to Tirzepatide or try Retatrutide for the additional glucagon mechanism
- Cutting-edge protocols: Retatrutide or CagriSema for the most advanced mechanisms currently available
- Stubborn lower-body fat: Add AOD9604 or HGH Fragment to any GLP-1 protocol for direct fat cell targeting
Shop All GLP-1 Peptides from PEPTARA Health
Semaglutide from $30 · Tirzepatide from $28 · Retatrutide from $70. 99%+ purity, COA included, cold-chain from NC. Questions? Text (704) 605-9477.
Browse GLP-1 Peptides →